

Clinical Evaluation of Overall Lens Fit of Delefilcon A
Contact Lenses of Different Diameters and Base Curves

STUDY ID

CLU484-P007

PROTOCOL VERSION 4.0

24 Jul 2025

NCT06884202



Device Protocol for CLU484-P007

**Title: Clinical Evaluation of Overall Lens Fit of Delefilcon A Contact
Lenses of Different Diameters and Base Curves**

Protocol Number:	CLU484-P007
Clinical Investigation Type:	Pivotal
Test Product:	Delefilcon A contact lenses
Sponsor Name and Address:	Alcon Research, LLC, and its affiliates (“Alcon”) 6201 South Freeway Fort Worth, Texas 76134-2099

***Property of Alcon
Confidential***

May not be used, divulged, published, or otherwise disclosed without the consent of Alcon

Investigator Agreement:

- I have read the clinical study described herein, recognize its confidentiality, and agree to conduct the described trial in compliance with Good Clinical Practices; applicable international and national regulations, laws, guidelines, and standards; the conditions of approval imposed by the reviewing IRB or regulatory authority; and in accordance with the ethical medical research principles outlined in the Declaration of Helsinki.
- I will supervise all testing of the device involving human subjects and ensure that the requirements relating to obtaining informed consent and IRB review and approval are met in accordance with applicable local and governmental regulations.
- I have read and understand the appropriate use of the investigational product(s) as described in the protocol, current investigator's brochure, product information, or other sources provided by the sponsor.
- I understand the potential risks and side effects of the investigational product(s).
- I agree to maintain adequate and accurate records in accordance with government regulations and to make those records available for inspection.
- I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements of the sponsor and government agencies.
- I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed of their obligations in meeting the above commitments.

Have you ever been disqualified as an investigator by any Regulatory Authority? ☐ No ☐ Yes
Have you ever been involved in a study or other research that was terminated? ☐ No ☐ Yes If yes, please explain here:

Principal investigator:

Signature

Date

Name and professional
position:

Address:

Table of Contents

Device Protocol for CLU484-P007	1
Table of Contents	3
List of Tables.....	6
List of Figures	6
1 GLOSSARY OF TERMS	7
2 LIST OF ACRONYMS AND ABBREVIATIONS	14
3 PROTOCOL SUMMARY	16
	
5 INTRODUCTION	25
5.1 Rationale and Background.....	25
5.2 Purpose of the Study.....	25
5.3 Risks and Benefits	26
6 STUDY OBJECTIVES.....	27
6.1 Primary Objective(s).....	27
	
6.4 Safety Objective(s)	28
7 INVESTIGATIONAL PLAN	29
7.1 Study Design.....	29
7.2 Rationale for Study Design.....	30
7.3 Rationale for Duration of Treatment/Follow-Up.....	30
7.4 Rationale for Choice of Comparator Product	30
7.5 Data Monitoring Committee.....	30
8 STUDY POPULATION	30
8.1 Inclusion Criteria	31
8.2 Exclusion Criteria	32
8.3 Rescreening of Subjects.....	33
9 TREATMENTS ADMINISTERED.....	33
9.1 Investigational Product(s).....	33
9.2 Other Medical Device or Medication Specified for Use During the Study.....	37

9.3	Treatment Assignment/Randomization	37
9.4	Treatment Masking.....	38
9.5	Accountability Procedures.....	39
9.6	Changes to Concomitant Medications, Treatments/Procedures	40
10	STUDY PROCEDURES AND ASSESSMENTS	40
10.1	Informed Consent and Screening	40
10.2	Description of Study Procedures and Assessments	41
10.2.1	Demographics.....	41
10.2.2	Medical History	41
10.2.3	Worn Lens Collection.....	41
10.2.4	Habitual Lens Information	41
10.2.5	VA with Habitual Spectacle Correction.....	42
10.2.6	Investigational Product Compliance.....	42
10.2.8	Keratometry: Effectiveness Assessment.....	42
10.2.9	VA with Study Lenses: Effectiveness Assessment	42
10.2.10	Lens Fit Assessments: Effectiveness Assessment	42
10.2.12	Adverse Event Collection: Safety Assessment.....	42
10.2.13	Slit Lamp Biomicroscopy: Safety Assessment.....	42
10.2.14	Device Deficiencies: Safety Assessment.....	43
10.2.15	Manifest Refraction and Best Corrected Visual Acuity with Manifest Refraction: Effectiveness and Safety Assessment.....	43
10.3	Unscheduled Visits	43
10.4	Unplanned Lens Replacement.....	44
10.5	Discontinued Subjects	44
10.5.1	Screen Failures	44
10.5.2	Discontinuations	44
10.5.3	Schedule of Procedures and Assessments for Subjects Discontinued from Investigational Product.....	45
10.6	Clinical Study Termination.....	45
10.6.1	Follow-up of Subjects after Study Participation has Ended	45
11	ADVERSE EVENTS AND DEVICE DEFICIENCIES	46
11.1	General Information	46
11.2	Monitoring for Adverse Events	49
11.3	Procedures for Recording and Reporting	49

11.4	Return Product Analysis	51
11.5	Unmasking of the Study Treatment	52
11.6	Follow-Up of Subjects with Adverse Events	52
11.7	Pregnancy in the Clinical Study	52
12	ANALYSIS PLAN	53
12.1	Subject Evaluability	53
12.2	Analysis Sets	53
12.2.1	Safety Analysis Set	53
12.2.2	Full Analysis Set	53
12.2.3	Per Protocol Analysis Set	53
12.3	Demographic and Baseline Characteristics	53
12.4	Effectiveness Analyses	54
12.4.1	Analysis of Primary Effectiveness Endpoint(s)	54
12.4.1.1	Statistical Hypotheses	55
12.4.1.2	Analysis Methods	56
		
12.5	Handling of Missing Data	58
12.6	Safety Analysis	58
12.7	Interim Analyses and Reporting	59
12.8	Sample Size Justification	59
13	DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS	59
13.1	Subject Confidentiality	59
13.2	Completion of Source Documents and Case Report Forms	60
13.3	Data Review and Clarifications	61
13.4	Sponsor and Monitoring Responsibilities	61
13.5	Regulatory Documentation and Records Retention	62
13.6	Quality Assurance and Quality Control	62
14	ETHICS	62
15	REFERENCES	64
15.1	Regulations and Standards	64
15.2	Scientific and Other References	65



List of Tables

Table 2-1 List of Acronyms and Abbreviations Used in This Protocol14

Table 3-1 Schedule of Study Procedures and Assessments22

Table 6-1 Primary Objective(s)27



Table 6-3 Safety Objective(s).....28

Table 9-1 Test Product33

Table 9-2 Comparator Product35



Table 12-1 Definition for the Primary Effectiveness Endpoints55



List of Figures

Figure 7-1 Study Design.....29

Figure 11-1 Categorization of All Adverse Events.....46

Figure 11-2 Categorization of All Serious Adverse Events.....47

1 GLOSSARY OF TERMS

Names of test product	Throughout this document, test product(s) will be referred to as LID023681
Name of comparator product	DAILIES TOTAL1® (LID006961)
Adverse device effect (ADE)	Adverse event related to the use of an investigational medical device or comparator. <i>Note: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation; any malfunction; and use error or intentional misuse.</i>
Adverse event (AE)	Untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device or comparator and whether anticipated or unanticipated. <i>Note: For subjects, this definition includes events related to the investigational medical device, comparator, or the procedures involved. For users or other persons, this definition is restricted to the use of the investigational medical device or comparator.</i> Requirements for reporting adverse events in the study can be found in Section 11.
Anticipated serious adverse device effect (ASADE)	An effect which by its nature, incidence, severity, or outcome has been identified in the risk assessment.

Clinical investigation plan (CIP)	The document(s) stating the rationale, objectives, design, and prespecified analysis, methodology, organization, monitoring, conduct, and record-keeping of the clinical investigation. <i>Note: The protocol and other documents referenced in the protocol (for example, the statistical analysis plan, the manual of procedures [MOP], the data evaluability plan, and the protocol monitoring plan) comprise the CIP.</i>
Clinical investigation report (CIR) / clinical study report	The document describing the design, execution, statistical analysis, and results of a clinical investigation. The clinical investigation report is synonymous with the clinical study report.
Device deficiency	Inadequacy of a medical device with respect to its identity, quality, durability, reliability, usability, safety, or performance. <i>Note: This definition includes malfunctions, use errors, and inadequacy in the information supplied by the manufacturer including labelling related to the investigational medical device or the comparator.</i> Requirements for reporting device deficiencies in the study can be found in Section 11.
Enrolled subject	Any subject who signs an informed consent form (ICF) for participation in the study.
Point of enrollment	The time at which, following recruitment and before any clinical investigation-related procedures are undertaken, a subject signs and dates the informed consent form.

Interventional clinical trial	A pre- or postmarket clinical investigation where the assignment of a subject to a particular medical device is decided in advance by a clinical investigation plan, or diagnostic or monitoring procedures requested in the CIP are in addition to those available as normal clinical practice and burden the subject.
Investigational product	A preventative (vaccine), a therapeutic (drug or biologic), device, diagnostic, or palliative used as a test or comparator product in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the authorized form, or when used for an unauthorized indication, or when used to gain further information about the authorized form.
Malfunction	Failure of an investigational medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use or clinical investigation plan (CIP), or investigator's brochure (IB).
Noninterventional study	Clinical investigation that draws inferences about the possible effect of an intervention on subjects, but the investigator has not assigned subjects into intervention groups based on a protocol and has not made any attempts to collect data on variables beyond those available throughout the course of normal clinical practice and burden to the subject. <i>Note: The term "noninterventional" is synonymous with "observational."</i>
Nonserious adverse event	Adverse event that does not meet the criteria for a serious adverse event.

Postmarketing / postauthorization study	Any study conducted within the conditions laid down in product labelling and other conditions laid down for the marketing of the product or under normal conditions of use. A postmarketing study falls either within the definitions of an interventional or a noninterventional study and may also fall within the definition of a postapproval study.
Product complaint	Any oral, electronic, or written communication that alleges deficiencies related to the identity (labeling), quality, durability, reliability, safety, effectiveness, or performance of a marketed product, including failure of the product, labeling, or packaging to meet specifications, whether or not the product is related to or caused the alleged deficiency. A complaint may allege that an adverse event or medical device malfunction has occurred.
Randomized subject	Any subject who is assigned a randomized treatment.
Serious adverse device effect (SADE)	Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.

Serious adverse event (SAE)	Adverse event that led to any of the following: • Death. • A serious deterioration in the health of the subject, users or other persons as defined by one or more of the following: a) a life-threatening illness or injury <i>Note: Life-threatening means that the individual was at immediate risk of death from the event as it occurred, i.e., it does not include an event which hypothetically might have caused death had it occurred in a more severe form.</i> b) any potentially sight-threatening event or permanent impairment to a body structure or a body function including chronic diseases. c) inpatient hospitalization or prolonged hospitalization. d) a medical or surgical intervention to prevent a) or b). e) any indirect harm as a consequence of incorrect diagnostic test results when used within manufacturer's instructions for use. • Fetal distress, fetal death, congenital abnormality or birth defect including physical or mental impairment. <i>Note: Planned hospitalization for a preexisting condition, or a procedure required by the CIP, without serious deterioration in health, is not considered a serious adverse event.</i> Refer to Section 11 for additional SAEs.
-----------------------------	---

Serious health threat	Signal from any adverse event or device deficiency that indicates an imminent risk of death or a serious deterioration in the health in subjects, users, or other persons, and that requires prompt remedial action for other subjects, users, or other persons. <i>Note: This would include events that are of significant and unexpected nature such that they become alarming as a potential serious health hazard or possibility of multiple deaths occurring at short intervals.</i>
Significant nonserious adverse event	A significant nonserious adverse event is a symptomatic, device-related, nonsight-threatening adverse event that warrants discontinuation of any contact lens wear for greater than or equal to 2 weeks. Refer to Section 11 for additional significant nonserious AEs.
Study start	The start of the study is considered to coincide with the enrollment of the first subject.
Study completion	The completion of the study is considered to coincide with the study-level last subject last visit or the decision to terminate the trial, whichever is later.
Unanticipated serious adverse device effect (USADE)	Serious adverse device effect which by its nature, incidence, severity, or outcome has not been identified in the risk assessment.

Use error	User action or lack of user action while using the medical device that leads to a different result than that intended by the manufacturer or expected by the user. <i>Note:</i> <i>a) Use error includes the inability of the user to complete a task.</i> <i>b) Use errors can result from a mismatch between the characteristics of the user, user interface, task, or use environment.</i> <i>c) Users might be aware or unaware that a use error has occurred.</i> <i>d) An unexpected physiological response of the subject is not by itself considered a use error.</i> <i>e) A malfunction of a medical device that causes an unexpected result is not considered a use error.”</i>
Vulnerable subject	An individual who is unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response.

2 LIST OF ACRONYMS AND ABBREVIATIONS

Table 2-1 List of Acronyms and Abbreviations Used in This Protocol

Abbreviation	Definition
ADE	Adverse device effect
AE	Adverse event
ASADE	Anticipated serious adverse device effect
BCVA	Best corrected visual acuity
CFR	Code of Federal Regulations
CI	Confidence interval
CIP	Clinical investigation plan
CIR	Clinical investigation report
COL	Clinical operations lead
CRF	Case report form
CSM	Clinical site manager
CTT	Clinical trial team
D	Diopter
D/C	Discontinued
DEP	Data evaluability plan
DT1	DAILIES TOTAL 1
eCRF	Electronic case report form
EDC	Electronic data capture
FAS	Full analysis set
FDA	US Food and Drug Administration
GCP	Good Clinical Practice
GPCMS	Global Product Complaint Management System
IB	Investigator's brochure
ICF	Informed consent form
IEC	Independent ethics committee
IP	Investigational product
IRB	Institutional review board
ISO	International Organization for Standardization
LCL	Lower confidence limit
LID	Lense identification
LogMAR	Logarithm of the minimum angle of resolution
mm	millimeter
MOP	Manual of procedures
MR	Manifest refraction
N	Number of subjects
N/A	Not applicable
NI	Noninferiority
OD	Right eye
OS	Left eye
PP	Per protocol

Abbreviation	Definition
PR #	Project record number
SADE	Serious adverse device effect
SAE	Serious adverse event
SD	Standard deviation
SLE	Slit lamp examination
SOP	Standard operating procedure
USA	United States of America
USADE	Unanticipated serious adverse device effect
USV	Unscheduled visit
VA	Visual acuity

3 PROTOCOL SUMMARY

Investigational Product Type	Device
Study Type	Interventional
Investigational Products	Test Product: LID023681 Comparator Product: DAILIES TOTAL1 (DT1) (LID006961)
Purpose and Scientific Rationale for the Study	The purpose of the study is to evaluate the lens fit characteristics of delefilcon A contact lenses of different base curves and diameters.
Brief Summary of the Protocol	This study aims to compare lens fit characteristics and subjective assessments of comfort and vision of delefilcon A soft contact lenses in two different configurations of base curve and diameter. This is a dispensing, randomized, crossover, bilateral wear study with 4 study visits. The sample size is ~270 subjects to enroll, and 175 subjects to complete. [REDACTED] [REDACTED] [REDACTED] The study will include volunteer subjects aged 18 or over who are habitual spherical soft contact lens wearers (including DT1 habitual wearers), wear contact lenses a minimum of 6 hours a day, and with a manifest refraction between -2.00 and -4.00 D. [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
Objectives	The primary objective of this study is to demonstrate noninferiority (NI) of LID023681 to LID006961, at Dispense and at 6 Hour Follow-up, in the following proportions for lens fit assessments: • Lenses with optimal and acceptable overall lens fit at primary gaze • Lenses with optimal and acceptable overall lens fit at peripheral gazes • Lenses with optimal and acceptable centration

	The safety objective of this study is to describe the safety profile of investigational products based on evaluation of adverse events, biomicroscopy findings, and device deficiencies.
Endpoints	Primary Effectiveness: • Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at primary gaze • Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at peripheral gazes • Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at Dispense, in lens position (centration) • Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at primary gaze • Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at peripheral gazes • Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at 6 Hour Follow-up, in lens position (centration)

	Safety • Adverse events • Biomicroscopy findings • Device deficiencies
Assessments	Effectiveness • Lens movement (overall lens fit) at primary and peripheral gazes • Lens position (centration) • Keratometry • Manifest refraction (MR) and best corrected visual acuity (BCVA) with MR • Unplanned lens replacement Safety • Adverse events

	• Biomicroscopy • Device deficiencies
Study Design	This is a prospective, randomized [REDACTED], crossover, double-masked study comparing LID023681 and LID006961 contact lenses. Subjects will be expected to attend 4 office visits and will wear the lenses for a minimum of 6 hours on each lens dispense day. Between Visits 2 and 3, a washout period (wearing spectacles) will be required.
Subject Population	Planned number of subjects enrolled/consented: ~270 Planned number of completed subjects: 175* [REDACTED] [REDACTED] [REDACTED]
Sites and Locations	Planned number of clinical sites: approximately 16 sites Planned locations (initial list of locations, which may change during start up or conduct according to study needs): United States
Key Inclusion Criteria (See Section 8.1 for a complete list of inclusion criteria)	• 18 years of age or over • Successful wearer of spherical soft contact lenses in both eyes for a minimum of 5 days per week and a minimum of 6 hours per day during the past 3 months • Able to wear contact lenses within a range of sphere powers from -2.00 and -4.00 D • BCVA (with manifest refraction) better than or equal to 0.10 (logMAR) in each eye
Key Exclusion Criteria (See Section 8.2 for a complete list of exclusion criteria)	• Any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator • History of refractive surgery or plan to have refractive surgery during the study, or irregular cornea in either eye • Biomicroscopy findings at screening that are moderate (Grade 3) or higher and/or corneal vascularization that is mild (Grade 2) or higher; presence of corneal infiltrates

**Data Analysis and
Sample Size
Justification**

Planned Data Analysis

To address the primary effectiveness [REDACTED]
[REDACTED] objectives, planned inferential analyses are summarized below:

Family Endpoint	Visit	Statistical Model
<i>Family 1</i>		
• P(acceptable/optimal) fit primary gaze • P(acceptable/optimal) fit peripheral gazes • P(acceptable/optimal) centration	Dispense	Generalized linear model with a logit link function NI margin = 0.05
<i>Family 2</i>		
• P(acceptable/optimal) fit primary gaze • P(acceptable/optimal) fit peripheral gazes • P(acceptable/optimal)	6 Hour	Generalized linear model with a logit link function NI margin = 0.05

No inferential testing will be performed for [REDACTED]
[REDACTED] safety endpoints.

Sample Size Justification

Sample size calculation is based on several base curve optimization studies with Alcon lens materials.

For the primary effectiveness endpoints based on lens fit assessments, a sample size of 175 will provide 90% power in rejecting the null hypothesis of inferiority (margin = 0.05; one-sided $\alpha = 0.05$) with the following assumptions: difference of 0 in


	the proportion of optimal or acceptable fits/decentration and 0.051 for proportion of discordant pairs.
Associated materials	Lubrication/rewetting drops will not be permitted.

Table 3-1 Schedule of Study Procedures and Assessments

Visit	Lens 1 (Period 1)		Lens 2 (Period 2)			Early Exit#	Unscheduled Visit (USV)
	Visit 1 Screening / Baseline/Dispense Lens 1	Visit 2 Follow-up Lens 1	Visit 3 Dispense Lens 2	Visit 4 Follow-up Lens 2/Exit			
		6 (+2) hours after Lens 1 dispense at Visit 1	1-2 days after Visit 2	6 (+2) hours after Lens 2 dispense at Visit 3		N/A	N/A
Informed consent	X						
Demographics	X						
Medical history	X	(X)	(X)	(X)		(X)	(X)
Concomitant medications	X	(X)	(X)	(X)		(X)	(X)
Inclusion/exclusion	X						
Habitual lens (brand, power), solution (brand if applicable)	X						
VA with habitual spectacle correction (OD, OS, logMAR distance)*	X	X	X	X		X	(X)
Keratometry	X					(X)	(X)
Manifest refraction	X	(X)	(X)	(X)		(X)	(X)
BCVA (OD, OS, logMAR distance with manifest refraction)	X	(X)	(X)	(X)		(X)	(X)

Visit	Lens 1 (Period 1)		Lens 2 (Period 2)		Early Exit#	Unscheduled Visit (USV)
	Visit 1 Screening / Baseline/Dispense Lens 1	Visit 2 Follow-up Lens 1	Visit 3 Dispense Lens 2	Visit 4 Follow-up Lens 2/Exit		
		6 (+2) hours after Lens 1 dispense at Visit 1	1-2 days after Visit 2	6 (+2) hours after Lens 2 dispense at Visit 3	N/A	N/A
Biomicroscopy	X	X	X	X	X	X
Randomize	X					
Dispense study lenses*	X		X			(X)
VA with study lenses (OD, OS, logMAR distance)	X ^Δ	X	X	X	X	(X)
Lens fit assessments (OD, OS) (study lenses):						
• Lens movement (overall fit) at primary gaze • Lens movement (overall fit) at peripheral gazes • Lens position (centration)	X	X	X	X	X	(X)

Visit	Lens 1 (Period 1)		Lens 2 (Period 2)		Early Exit#	Unscheduled Visit (USV)
	Visit 1 Screening / Baseline/Dispense Lens 1	Visit 2 Follow-up Lens 1	Visit 3 Dispense Lens 2	Visit 4 Follow-up Lens 2/Exit		
		6 (+2) hours after Lens 1 dispense at Visit 1	1-2 days after Visit 2	6 (+2) hours after Lens 2 dispense at Visit 3	N/A	N/A



Unplanned lens replacement	(X)		(X)			
Subject instructions (verbal)*	X	X	X			(X)
Collect worn lenses*		X		X	X	(X)
Adverse events	X	X	X	X	X	X
Device deficiencies	X	X	X	X	X	X
Exit form	(X)	(X)	(X)	X	X	(X)

(X) assessment performed as necessary, e.g., decrease of VA by 2 lines or more with investigational product (IP)

* Source only

Δ Reassess lens power (and dispense different power(s), if applicable) if VA has decreased by 2 lines or more from BCVA with MR. If lens is changed, repeat VA.

#If subject exits during a scheduled visit, assessments should be recorded in EDC in the Early Exit form, and the Visit should be updated to “not done due to Early Exit.”

4 PROTOCOL AMENDMENTS

Modification of the protocol is prohibited without prior written agreement in the form of a protocol amendment. All amendments must be created by the study sponsor and must be approved by the institutional review board (IRB)/independent ethics committee (IEC) and global and regional health authorities, as applicable, prior to implementation except when required to mitigate immediate safety risks or when the changes involve only logistical or administrative revisions.

Amendments may necessitate that the informed consent and other study-related material be revised. If the consent form is revised, all subjects currently enrolled in the study must sign the approved, revised informed consent (re-consent), as required by the IRB/IEC.



5 INTRODUCTION

5.1 Rationale and Background

LID006961 contact lenses, made of delefilcon A, were introduced with a unique dual technology that combines a low water content silicone hydrogel core to achieve optimal oxygen supply, with a high water content hydrogel surface to provide a highly lubricious, wettable lens. Previous studies support the hypothesis that Water Gradient Technology in LID006961 lenses produces superior clinical performance and subjective acceptance. In addition, the low modulus and other material properties of delefilcon A enable flexibility of lens fit for different corneal curvatures and diameters.

5.2 Purpose of the Study

The purpose of the study is to evaluate the lens fit characteristics of delefilcon A contact lenses of different base curves and diameters. The endpoints for this study were selected to fulfill the primary [REDACTED] objectives of the study. Procedures for measurement of these endpoints were selected based on common practice for these assessments. The design of this study is justified based upon preclinical and clinical testing, as described within the package insert. Commercial LID006961 contact lenses were chosen as the comparator product because these lenses have the same wear modality, material, and indication for use.

At the end of the study, a clinical study report will be prepared in accordance with applicable regulatory requirements and standards.

There are no immediate plans to submit the results of this study for publication; however, the results may be offered for publication if they are of scientific interest, or if the results relate to a product that is subsequently approved or cleared for marketing.

Alcon reserves the right of prior review of any publication or presentation of information related to the study. The author(s) of the publication will be the individual with substantial contribution to the conception or design of the work, OR the acquisition, analysis, or interpretation of data. Additionally, the author will draft the work or revise it critically for important intellectual content; provide final approval of the version to be published; and agree to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

5.3 Risks and Benefits

Risk management principles have been applied to both the planning and the intended conduct of the clinical investigation, in order to ensure the reliability of the clinical data generated and the safety of the subjects.

The clinical investigation process risks are managed through appropriate training and monitoring according to the protocol-specific monitoring plan. Investigational device risks, including risks associated with use of device and methods and procedures for application of device, are defined in the package insert product labeling and are managed through review of safety assessments outlined in this protocol.

Contact lenses may offer improved peripheral vision and the convenience of not wearing spectacles. Material properties and design characteristics of delefilcon A contact lenses are features consistent with successful contact lens wear. Based upon nonclinical testing and historic clinical studies with delefilcon A contact lenses, the study lenses within this study are nontoxic and biocompatible for on-eye use.

There may also be unknown risks to use of the test product. Any risk to subjects in this clinical study will be minimized by compliance with the eligibility criteria and study procedures, clinical oversight, and monitoring. Site personnel will educate subjects on proper hygiene and lens handling, and compliance with the use of contact lenses for daily wear according to the protocol. Subjects should be instructed not to wear contact lenses while swimming, due to increased risk of infection, or while sleeping. Site personnel should advise the subjects to remove contact lenses and return for prompt follow-up of symptoms such as ocular discomfort, foreign body sensation, excessive tearing, vision changes, or hyperemia.

Refer to the product package insert for additional information.

6 STUDY OBJECTIVES

6.1 Primary Objective(s)

Table 6-1 Primary Objective(s)

<u>Objective(s)</u>	<u>Endpoint(s)</u>
To demonstrate noninferiority of LID023681 to LID006961, at Dispense and at 6 Hour Follow-up, in the proportions of optimal/acceptable lenses for lens fit assessments.	- Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at primary gaze - Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at peripheral gazes - Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at Dispense, in lens position (centration) - Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at primary gaze - Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at peripheral gazes - Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at 6 Hour Follow-up, in lens position (centration)



6.4 Safety Objective(s)

Table 6-3 **Safety Objective(s)**

<u>Objective(s)</u>	<u>Endpoint(s)</u>
To describe the safety profile of the investigational products.	• Adverse events • Biomicroscopy findings • Device deficiencies


7 INVESTIGATIONAL PLAN

7.1 Study Design

This is a prospective, randomized [REDACTED] crossover, double-masked study comparing LID023681 and LID006961 contact lenses.

Subjects will be randomized to 1 of 2 crossover sequences and exposed to both test and comparator lenses for bilateral wear. Subjects will be expected to attend 4 office visits and will be dispensed study lenses (test and comparator lenses), on Day 1 on each period for a 6 (+2) hour duration of bilateral wear each. A washout period (wearing spectacles) after the end of Visit 2 will be required. The investigator will be masked to the dispensed study lenses. The subjects will be masked to the dispensed study lenses. An unmasked site coordinator will prepare the lenses for dispensing.

Figure 7-1 Study Design



7.2 Rationale for Study Design

This study design is justified based upon an evaluation of the results of relevant preclinical and clinical testing.

The crossover design will ensure that the same subject is exposed to both the test and comparator lens parameters; therefore, both objective assessments and subjective responses will be obtained for both lenses from the same subject. The study will include only those subjects who are current wearers of spherical soft contact lenses in both eyes. This will avoid confounding subjective and safety responses in nonadapted subjects, as described within the package insert.

7.3 Rationale for Duration of Treatment/Follow-Up

Subjects will wear each study product bilaterally for 6 to 8 hours. The lenses will be provided by a qualified unmasked study staff member in such a manner that the subject and the investigator remain masked to the lens type. Effectiveness endpoints will be assessed at dispense and follow-up visits for each study product.

7.4 Rationale for Choice of Comparator Product

Commercial LID006961 is the comparator because of the same lens manufacturing process, material, and indication for use as the test lens, only differing in base curve and diameter.

7.5 Data Monitoring Committee

Not applicable.

8 STUDY POPULATION

The study population consists of volunteer subjects, of at least 18 years of age, who are habitual spherical soft contact lens wearers in both eyes for a minimum of 5 days per week and minimum 6 hours per day during the past 3 months. It is aimed to enroll (consent) approximately 270 subjects in approximately 16 sites throughout the United States, with a target of 175 total subjects exposed and completed, with 10 (intended minimum) to approximately 20 subjects per site. Site-specific targets may vary based upon individual site capabilities. [REDACTED]

[REDACTED] Estimated time needed to recruit subjects for the study is approximately 7 weeks; however, unanticipated circumstances may shorten or lengthen this time and would not require amendment of this protocol.



8.1 Inclusion Criteria

Written informed consent must be obtained before any study specific assessment is performed. Upon signing informed consent, the subject is considered enrolled in the study.

Subjects eligible for inclusion in this study must fulfill **all** of the following criteria:

1. Must be able to understand and sign an IRB/IEC approved informed consent form.
2. Willing and able to attend all scheduled study visits as required per protocol.
3. Must be at least 18 years of age.
4. Successful wearer of spherical soft contact lenses in both eyes for a minimum of 5 days per week and minimum 6 hours per day during the past 3 months.
5. Manifest cylinder ≤ 0.50 D in each eye.
6. BCVA (with manifest refraction), better than or equal 0.10 (logMAR distance) in each eye.
7. Able to wear contact lenses within a range of sphere powers from -2.00 to -4.00 D (0.50 D steps).
8. Must possess spectacles and be willing to wear them for vision correction when study lenses are not worn, as needed, including during washout period following Visit 2.

9. Must be willing to stop habitual contact lens wear for the duration of study participation.

8.2 Exclusion Criteria

Subjects fulfilling **any** of the following criteria are not eligible for participation in this study.

1. Any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator.
2. Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator.
3. History of refractive surgery or plan to have refractive surgery during the study or irregular cornea in either eye.
4. Ocular or intraocular surgery (excluding placement of punctual plugs) within the previous 12 months or planned during the study.
5. Biomicroscopy findings at screening that are moderate (Grade 3) or higher and/or corneal vascularization that is mild (Grade 2) or higher; presence of corneal infiltrates.
6. Current or history of pathologically dry eye in either eye that, in the opinion of the investigator, would preclude contact lens wear.
7. Current or history of herpetic keratitis in either eye.
8. Eye injury in either eye within 12 weeks immediately prior to enrollment for this trial.
9. Current or history of intolerance, hypersensitivity, or allergy to any component of the study products.
10. Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment.
11. Any use of topical ocular medications and artificial tear or rewetting drops during the study.
12. The investigator, his/her staff, family members of the investigator, family members of the investigator's staff, or individuals living in the households of the aforementioned persons may not participate in the study.
13. Participation in a clinical trial within the previous 10 days or currently enrolled in any clinical trial.

8.3 Rescreening of Subjects

Rescreening of subjects is not allowed in this study.

9 TREATMENTS ADMINISTERED

9.1 Investigational Product(s)

Test Product(s): LID023681

Comparator Product(s) (If applicable): DAILIES TOTAL1 (LID006961)

Table 9-1 Test Product

Test product	LID023681
Manufacturer	Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134-2099 USA
Indication for use and intended purpose in the current study	Indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with nondiseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
Product description and parameters available for this study	- Material: delefilcon A – 67% - Water content: 33% - Power range: lens parameters of the investigational product will be provided, as available: -2.00 D, -2.50 D, -3.00 D, -3.50 D, and -4.00 D - Base curve (mm): 8.8 - Diameter (mm): 14.4
Formulation	Refer to DT1 package insert.
Usage	- Wear: - Daily wear - Bilateral - Replacement period: Daily disposable

	• Exposure: At least 6 to 8 hours per day, per study visit day • Lens care: N/A
Number/Amount of product to be provided to the subject	Lenses (to be used for study lens wear) will be provided in bulk by the sponsor. Spare lenses will not be provided. See MOP for more details.
Packaging description	Blister foil pack
Labeling description	• Lens foil label includes: - material name and identifier - base curve - diameter - packing solution - power - lot number - expiration date - content statement - investigational device statement - sponsor information Lens inventory will be provided in packages and identified with the following: • a color-coded label stating the study protocol number/lens identification (LID) number • power • an investigational use only statement • handling unit/tracking number
Training and/or experience requirements for device	No additional training or experience is required to administer the test product.
Storage conditions	Lenses are to be stored at room temperature

Additional information	N/A
Supply	Test lenses will be provided by the sponsor Refer to the MOP for a detailed description

Table 9-2 Comparator Product

Comparator product	DAILIES TOTAL1 (LID006961)
Manufacturer	Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134-2099 USA
Indication for use	Indicated for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with nondiseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity
Product description and parameters available for this study	• Material: delefilcon A – 67% • Water content: 33% • Power range: lens parameters of the investigational product will be provided, as available: ○ -2.00 D, -2.50 D, -3.00 D, -3.50 D, and -4.00 D • Base curve (mm):8.5 • Diameter (mm): 14.1
Formulation	Refer to package insert
Usage	• Wear: ○ Daily wear ○ Bilateral • Replacement period: Daily disposable • Exposure: At least 6 to 8 hours per day, per study visit day • Lens Care: N/A
Number/Amount of product to be	Lenses (to be used for study lens wear) will be provided in bulk by the sponsor.

provided to the subject	
Packaging description	Blister foil pack
Labeling description	• Lens foil label includes: - material name and identifier - base curve - diameter - packing solution - power - lot number - expiration date - content statement - investigational device statement - sponsor information Lens inventory will be provided in packages and identified with the following: • a color-coded label stating the study protocol number/LID number • power • an investigational use only statement • handling unit/tracking number
Training and/or experience requirements for device	No additional training or experience is required to administer the comparator.
Storage conditions	Lenses are to be stored at room temperature
Additional identifying information	N/A
Supply	Comparator lenses will be provided by the sponsor Refer to the MOP for a detailed description

More information on the test and comparator products can be found in the package insert for DAILIES TOTAL1.

9.2 Other Medical Device or Medication Specified for Use During the Study

No other medical devices or medications are required to be used in conjunction with the treatments during the clinical study.

9.3 Treatment Assignment/Randomization

A [REDACTED] randomization will be implemented for this study.



Subjects will be randomized in a 1:1 ratio to receive treatment (lens) in 1 of the following crossover sequences:

Sequence 1: LID023681/LID006961

Sequence 2: LID006961/LID023681

Only after signing the ICF, a subject will be assigned a subject number by the electronic data capture system.

A randomization list will be generated using a validated system that automates the random assignment of treatments (lens sequences) to randomization numbers in the specified ratio. Subjects will be assigned treatment (lens) according to the randomization list uploaded in the randomization system. The randomization list will be generated and maintained by the study sponsor.

At Visit 1, all eligible subjects will be randomized via the electronic data capture (EDC) randomization system to one of the treatments (lens sequences). The investigator or delegate will access the respective system after confirming that the subject meets all the eligibility criteria. A randomization number will be automatically assigned to the subject according to

the subject randomization list but will not be communicated to the site user. The EDC randomization system will inform the site user of the treatment (lens sequence) assignment to be dispensed to the subject.

9.4 Treatment Masking

This study is double-masked, with subjects randomized to use LID023681 or LID006961 for the duration of 6 to 8 hours per lens wear period. All members associated with the study (at the site and the study sponsor) are masked to the assigned treatment (lens sequence) with the exception of:



This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked.

Masked study personnel must avoid seeking information that may compromise masking. Unmasked study personnel must not disseminate information that is potentially unmasking to any masked personnel. The masked and unmasked site personnel must coordinate all study activities as necessary to protect masking and minimize bias during the study.

In the event of a medical emergency where the knowledge of subject treatment is required, an individual investigator will have the ability to unmask the treatment assignment for a specific subject after contacting an appropriate study sponsor representative if time allows.

9.5 Accountability Procedures

Upon receipt of the IP, the investigator or delegate must conduct an inventory. During the study, the unmasked delegate must provide the IPs for the subjects in accordance with their randomization assignment. Throughout the study, the unmasked delegate must maintain records of IP dispensation and collection for each subject. This record must be made available

to the study monitor for the purposes of verifying the accounting of IP supplies. Any discrepancies and/or deficiencies between the observed disposition and the written account must be recorded along with an explanation. All IPs sent to the investigator must be accounted for by study sponsor personnel, and in no case be used in an unauthorized situation.

It is the investigator's responsibility to ensure that:

- All study products are accounted for and not used in any unauthorized manner
- All unused products are available for return to the study sponsor, as directed
- Any study lenses associated with a device deficiency or with any product-related adverse event (i.e., ADE or SADE) are returned to the study sponsor for investigation, unless otherwise directed by the sponsor. Refer to Section 11 of this protocol for additional information on the reporting of device deficiencies and AEs and the return of study products associated with these events.

The investigator is responsible for proper disposition of all unused IPs at the conclusion of the study, according to the instructions provided in the MOP.

9.6 Changes to Concomitant Medications, Treatments/Procedures

After the subject is enrolled into the study, the investigator must instruct the subject to notify the study site about:

- Any new medications
- Alterations in dose or dose schedules for current medications
- Any medical procedure or hospitalization that occurred or is planned
- Any nondrug therapies (including physical therapy and blood transfusions)

The investigator must document this information in the subject's case history source documents.

10 STUDY PROCEDURES AND ASSESSMENTS

10.1 Informed Consent and Screening

The investigator or delegate must explain the purpose and nature of the study, and have the subject read, sign, and date the IRB/IEC-approved informed consent document. The subject must sign the ICF BEFORE any study-specific procedures or assessments can be performed, including study-specific screening procedures. Additionally, have the individual obtaining

consent from the subject and a witness, if applicable, sign and date the informed consent document.

The investigator or delegate must provide a copy of the signed document to the subject and place the original signed document in the subject's chart, or provide documentation as required by local regulations.

10.2 Description of Study Procedures and Assessments

Study-specific procedures and assessments described here may include standard of care; other standard of care procedures performed in the clinical management of the subject are not excluded.

Detailed descriptions of assessments and procedures are provided in the MOP. The investigator is responsible for ensuring responsibilities for all procedures and assessments are delegated to appropriately qualified site personnel.

10.2.1 Demographics

Obtain demographic information including age, race, ethnicity, and sex.

10.2.2 Medical History

Collect medical history information, including information on all medications used within the past 30 days. Include herbal therapies, vitamins, and all over-the-counter as well as prescription medications. Throughout the subject's participation, obtain information on any changes in medical health and/or the use of concomitant medications.

Targeted medical history and concomitant medications will be collected in the electronic case report form (eCRF) as outlined in the MOP.

10.2.3 Worn Lens Collection

Worn lenses will be collected from subject and returned to unmasked study staff at the site for disposal. Refer to MOP for details.

10.2.4 Habitual Lens Information

At Visit 1, the subject's habitual contact lens information will be collected. Refer to MOP for details.

10.2.5 VA with Habitual Spectacle Correction

VA (logMAR distance; OD, OS) with the subject's habitual spectacle correction will be collected at all visits and is optional at Unscheduled Visits. Refer to MOP for details.

10.2.6 Investigational Product Compliance

Review subject compliance with the IP usage and collect all used study IPs and other products that were dispensed.

10.2.8 Keratometry: Effectiveness Assessment

Keratometry is required at Visit 1, and as necessary for Early Exit or Unscheduled Visits. Refer to MOP for details.

10.2.10 Lens Fit Assessments: Effectiveness Assessment

Lens fitting assessments with study lenses will be performed at all Visits and is optional at Unscheduled Visit. Refer to the MOP for details.

10.2.12 Adverse Event Collection: Safety Assessment

Assess and record any adverse events that are observed or reported since the previous visit, including those associated with changes in concomitant medication dosing.

10.2.13 Slit Lamp Biomicroscopy: Safety Assessment

SLE of the cornea, adnexa, and anterior segment of the eye must be performed in both eyes before instillation of any diagnostic eye drops.

10.2.14 Device Deficiencies: Safety Assessment

Assess and record any device deficiencies that are reported or observed since the previous visit. Requirements for reporting device deficiencies in the study can be found in Section 11.

10.2.15 Manifest Refraction and Best Corrected Visual Acuity with Manifest Refraction: Effectiveness and Safety Assessment

Manifest refraction and BCVA with MR will be completed at Visit 1, and other visits as applicable. LogMAR BCVA with manifest refraction testing for both eyes must be performed prior to any assessment requiring administration of eye drops to dilate the eyes, or any assessment requiring contact with the eye. Refer to MOP for details.

10.3 Unscheduled Visits

If a subject visit occurs between any regularly scheduled visit and the visit is conducted by study personnel, this visit must be documented as an Unscheduled Visit. If the subject seeks medical attention outside the clinic (for example, at an emergency room) or at the clinic but is seen by nonstudy personnel, the investigator is to capture adverse event-related information on the adverse event form upon becoming aware.

During all Unscheduled Visits, the investigator must conduct the following procedures:

- Collect adverse event information
- Collect device deficiency information, as applicable
- Record changes in medical condition or concomitant medication, as applicable
- Perform slit lamp biomicroscopy exam

The investigator may perform additional procedures for proper diagnosis and treatment of the subject. The investigator must document this information in the subject's case history source documents.

If during an Unscheduled Visit the subject is discontinuing the IP or discontinuing from the study, the investigator must conduct Exit procedures according to [Table 3-1](#) and Section [10.5.3](#), as possible.

Do not complete an Unscheduled Visit if a subject is exiting between scheduled study visits. An Early Exit Visit should be completed instead.

10.4 Unplanned Lens Replacement

No spare lenses will be dispensed to the subject. If, after the subject leaves the office and the lens is lost or damaged, no replacement lens will be dispensed.

If, during a dispensing visit, the lens needs to be replaced due to VA (Visit 1), lost/dropped lens or a device deficiency/ADE, the investigator can replace the lens and then repeat all applicable assessments.

Refer to MOP for details.

10.5 Discontinued Subjects

10.5.1 Screen Failures

Subjects who were excluded from the study after signing the informed consent and prior to randomization to product/dispense of study product are considered screen failures.

The investigator must document the reason for screen failure in the subject's case history source documents.

Subject numbers must not be re-used.

10.5.2 Discontinuations

Discontinued subjects are individuals who voluntarily withdraw or are withdrawn from the study by the investigator after signing informed consent and after randomization.

Subject numbers of discontinued subjects must not be re-used (i.e., subject replacement is not allowed).

Subjects may discontinue from study or study treatment at any time for any reason. Subjects may also be discontinued from study treatment at any time if, in the opinion of the investigator, continued treatment poses a risk to their health.

If a subject discontinues from study treatment, every effort must be made to keep the subject in the study and to continue with the study assessments as specified in the Schedule of Study Procedures and Assessments until the final visit.

For subjects discontinuing from the study, the investigator must complete all Exit procedures according to [Table 3-1](#) if the subject is willing and able, and if in the opinion of the investigator it is safe for the subject to do so.

The investigator must document the reason for study or treatment discontinuation in the subject's case history source documents.

To ensure the safety of all subjects who discontinue early, investigators must assess each subject and, if necessary, advise them of any therapies and/or medical procedures that may be needed to maintain their health.

10.5.3 Schedule of Procedures and Assessments for Subjects Discontinued from Investigational Product

Other than screen failures, if a subject discontinues from the study, the subject should undergo an Early Exit Visit, as possible. Refer to [Table 3-1](#) and the MOP for details.

10.6 Clinical Study Termination

The study sponsor reserves the right to suspend or close the investigational site or suspend or terminate the study in its entirety at any time.

If the clinical study is prematurely terminated or suspended by the study sponsor:

- The study sponsor must:
 - Immediately notify the investigator(s) and subsequently provide instructions for study termination.
 - Inform the investigator and the regulatory authorities of the termination/suspension and the reason(s) for the termination/suspension.
- The investigator must:
 - Promptly notify the IRB/IEC of the termination or suspension and of the reasons.
 - Provide subjects with recommendations for poststudy treatment options as needed.

The investigator may terminate the site's participation in the study for reasonable cause.

Breaking of the masked treatment codes will be done after locking the database.

10.6.1 Follow-up of Subjects after Study Participation has Ended

Following this study, the subject will return to their eye care professional for their routine eye care.

11 ADVERSE EVENTS AND DEVICE DEFICIENCIES

11.1 General Information

An AE is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the investigational medical device (test product). Refer to the Glossary of Terms and figures below for categories of AEs and SAEs.

Figure 11-1 **Categorization of All Adverse Events**





Figure 11-2 Categorization of All Serious Adverse Events



Specific Events Relevant to this Protocol

Serious Adverse Events

In addition to reporting all AEs (serious and nonserious) meeting the definitions, the investigator must report any occurrence of the following as an SAE:

- An ocular infection including a presumed infectious ulcer with any of the following characteristics:
 - Central or paracentral location
 - Penetration of Bowman’s membrane
 - Infiltrates > 2 mm diameter
 - Iritis
 - Increase in intraocular pressure
 - Culture positive for microorganisms

- Increasing size or severity at subsequent visits
- Any central or paracentral corneal event (such as neovascularization) that results in permanent opacification
- Hypopyon
- Hyphema
- Neovascularization within the central 6 mm of the cornea
- Permanent vision loss as defined by loss of 2 or more lines of BCVA (e.g., with manifest refraction or habitual correction) from enrollment visit that fails to resolve
- Uveitis (anterior, intermediate, or posterior)
- Corneal abrasion affecting $\geq 50\%$ of corneal surface area

Significant Nonserious Adverse Events

A significant nonserious AE is a device-related, nonsight threatening adverse event that warrants discontinuation of any contact lens wear for greater than or equal to 2 weeks. In addition, the investigator must report any occurrence of the following as a significant nonserious adverse event:

- Peripheral nonprogressive noninfectious ulcers
- All symptomatic corneal infiltrative events
- Corneal staining score greater than or equal to Grade 3 (Refer to MOP for grading scales)
- Temporary vision loss as defined by loss of 2 or more lines of BCVA (e.g., with manifest refraction or habitual correction) from enrollment visit that persists for 2 or more weeks
- Neovascularization score greater than or equal to Grade 2 (Refer to MOP for grading scales)

The above events are based on the categories provided in the International Organization for Standardization (ISO) 11980 and the US Food and Drug Administration (FDA) Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses and Lens Care.

Device Deficiencies

A device deficiency is inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance. A device deficiency may or may not be

associated with subject harm (i.e., ADE or SADE); however, not all ADEs or SADEs are due to a device deficiency. The investigator should determine the applicable category listed in the Device Deficiency eCRF for the identified or suspected device deficiency and report any subject harm separately. Examples of device deficiencies include the following:

- Failure to meet product specifications (e.g., incorrect lens power/diameter/base curve/color)
- Lens/solution cloudy
- Lens surface/edge defect
- Torn lens during handling/in pack
- Packaging deficit (e.g., mislabeled product, tampered seal, leaking bottle/container)
- Suspect product contamination

11.2 Monitoring for Adverse Events

At each visit, after the subject has had the opportunity to spontaneously mention any problems, the investigator should inquire about AEs by asking the standard questions shown below and report as applicable:

- “Have you had any health problems since your last study visit?”
- “Have there been any changes in the medicines you take since your last study visit?”

In addition, changes in any protocol-specific parameters and/or questionnaires evaluated during the study are to be reviewed by the investigator. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response that is clinically relevant, in the opinion of the investigator, is to be reported as an AE. These clinically relevant changes will be reported regardless of causality.

11.3 Procedures for Recording and Reporting

AEs are collected from the time of informed consent. Any preexisting medical conditions or signs/symptoms present in a subject prior to the start of the study (i.e., before informed consent is signed) are not considered AEs in the study and should be recorded in the medical history source document, and the eCRF, if applicable.

In addition, temporary lens awareness or visual changes during the fitting process are not considered AEs if the investigator assesses that the symptom(s) can reasonably resolve within the anticipated adaptation period.

For each recorded event, the ADEs and SAEs documentation must include date of occurrence, severity, treatment (if applicable), outcome, and assessments of the seriousness and causality. In addition, the investigator must document all device deficiencies reported or observed with test and comparator products on the Device Deficiency eCRF. The site must submit all available information on ADEs, SAEs, and device deficiencies to the study sponsor immediately as follows:

- ADEs or SAEs are documented on the Adverse Device Effect and Serious Adverse Event eCRF within 24 hours of the investigator's or site's awareness.
- Device deficiencies are documented on the Device Deficiency eCRF within 24 hours of the investigator's or site's awareness.
- Additional relevant information after initial reporting must be entered into the eCRF as soon as the data become available.
- Document any changes to relevant concomitant medications on the narrative section of the corresponding Adverse Device Effect (for related AEs) and Serious Adverse Event eCRF.
- Document all relevant information from discharge summary, autopsy report, certificate of death, etc., if applicable, in narrative section of the Adverse Device Effect (for related AEs) and Serious Adverse Event eCRF.

Note: Should the EDC system become nonoperational, the site must complete the appropriate paper Serious Adverse Event and Adverse Device Effect and/or Device Deficiency Form. The completed form is emailed to the study sponsor at msus.safety@alcon.com, for US, according to the timelines outlined above; however, the reported information must be entered into the EDC system once it becomes operational.

Study sponsor representatives may be contacted for any protocol-related question and their contact information is provided in the MOP that accompanies this protocol.

Further, depending upon the nature of the AE or device deficiency being reported, the study sponsor may request copies of applicable portions of the subject's medical records. The investigator must also report all AEs and device deficiencies that could have led to a SADE according to the requirements of regulatory authorities or IRB/IEC.

Intensity and Causality Assessments

Where appropriate, the investigator must assess the intensity (severity) of the AE based on medical judgment with consideration of any subjective symptom(s), as defined below:

Intensity (Severity)

Mild	An AE is mild if the subject is aware of but can easily tolerate the sign or symptom.
Moderate	An AE is moderate if the sign or symptom results in discomfort significant enough to cause interference with the subject's usual activities.
Severe	An AE is severe if the sign or symptom is incapacitating and results in the subject's inability to work or engage in their usual activities.

For every AE in the study, the investigator must assess the causality (related or not related to the medical device or study procedure). An assessment of causality will also be performed by study sponsor utilizing the same definitions, as shown below:

Causality

Related	An AE classified as related may be either definitely related or possibly related where a direct cause and effect relationship with the medical device or study procedure has not been demonstrated, but there is a reasonable possibility that the AE was caused by the medical device or study procedure.
Not Related	An AE classified as not related may either be definitely unrelated or simply unlikely to be related (i.e., there are other more likely causes for the AE).

The study sponsor will assess the AEs and may upgrade the investigator's assessment of seriousness and/or causality. The study sponsor will notify the investigator of any AE that is upgraded from nonserious to serious or from unrelated to related.

11.4 Return Product Analysis

Study sponsor representatives and their contact information are provided in the MOP that accompanies this protocol.

Alcon study products associated with device deficiencies and/or product related AEs should be returned and must include the project record number (PR #), which will be provided by

study sponsor after the case is entered in the study sponsor's Global Product Complaint Management System (GPCMS).

11.5 Unmasking of the Study Treatment

Masked information on the identity of the assigned medical device should not be disclosed during the study. If the assigned treatment needs to be unmasked in the interest of subject safety, the investigator is encouraged to contact an appropriate study sponsor representative prior to unmasking the information if there is sufficient time. Dependent upon the individual circumstances (i.e., medical emergency), the assigned treatment can be unmasked prior to contact with the study sponsor. The study sponsor must be informed of all cases in which unmasking occurred and of the circumstances involved. Additionally, the study sponsor may be required to unmask the information in order to fulfill expedited regulatory reporting requirements.

11.6 Follow-Up of Subjects with Adverse Events

The investigator is responsible for adequate and safe medical care of subjects during the study and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the study.

The investigator should provide the study sponsor with any new safety information (which includes new AEs and changes to previously reported AEs) that may affect the safety evaluation of the device. For AEs that are unresolved/ongoing at time of subject exit from study, any additional information received at follow-up should be documented in the eCRFs up to study completion (i.e., database lock).

All complaints received after this time period will be considered and processed as spontaneous (following the postmarket vigilance procedures) and should be communicated to the medical device's manufacturer as per local requirements.

11.7 Pregnancy in the Clinical Study

Women who are pregnant (as stated by subject) at the time of study entry are **not** excluded from participation. However, pregnancy should be included in the Pregnancy eCRF if a woman is pregnant at the study entry or becomes pregnant (as stated by the subject) during the study. Pregnancy is not reportable as an AE; however, complications may be reportable and will be decided on a case-by-case basis.

12 ANALYSIS PLAN

Continuous variables will be summarized using the number of observations, mean, standard deviation (SD), median, minimum, and maximum, as well as confidence intervals (CIs) or confidence limits where applicable. Categorical variables will be summarized with frequencies and percentages from each category.

Any deviations to the analysis plan will be updated during the course of the study as part of a protocol amendment or will be detailed in the clinical study report.

12.1 Subject Evaluability

Final subject evaluability must be determined prior to breaking the code for masked treatment (lens sequence) assignment and locking the database, based upon the data evaluability plan (DEP).

12.2 Analysis Sets

12.2.1 Safety Analysis Set

Safety analyses will be conducted using the safety analysis set on a treatment-emergent basis. As such, the safety analysis set will include all subjects/eyes exposed to any study product evaluated in this study. For treatment-emergent safety analyses, subjects/eyes will be categorized under the actual study product exposed in the corresponding sequence.

12.2.2 Full Analysis Set

The full analysis set (FAS) will include all randomized subjects exposed to any study lens.

12.2.3 Per Protocol Analysis Set

The per protocol (PP) analysis set is a subset of FAS and excludes all data/subjects that have met any of the critical deviation or evaluability criteria identified in the DEP.

12.3 Demographic and Baseline Characteristics

Demographic information and baseline characteristics will be summarized by lens sequence and overall. Frequencies and percentages will be presented for categorical variables such as sex and age group. Number of observations, mean, SD, median, minimum, and maximum will be presented for continuous variables such as age.

12.4 Effectiveness Analyses

This study defines six primary effectiveness endpoints, [REDACTED]. All effectiveness evaluations will use the full analysis set as the primary analysis set. Supportive analyses of the primary effectiveness endpoints [REDACTED] will be conducted using the PP analysis set only if the number of subjects excluded from the PP analysis set exceeds 5% of the FAS.

All effectiveness analyses will be carried out based on the randomization assignment.



12.4.1 Analysis of Primary Effectiveness Endpoint(s)

The primary objective of this study is to demonstrate noninferiority of LID023681 to LID006961, at Dispense and at 6 Hour Follow-up, in each of the following proportions based on lens fit assessments:

- Lenses with optimal and acceptable overall lens fit at primary gaze
- Lenses with optimal and acceptable overall lens fit at peripheral gazes
- Lenses with optimal and acceptable centration

The primary endpoints are:

- Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at primary gaze
- Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at Dispense, in lens movement (overall lens fit) at peripheral gazes
- Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at Dispense, in lens position (centration)
- Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at primary gaze
- Proportion of lenses graded as Acceptably Tight, Optimal Fit, or Acceptably Loose at 6 Hour Follow-up, in lens movement (overall fit) at peripheral gazes
- Proportion of lenses graded as Optimal Lens Centration or Acceptable Decentration at 6 Hour Follow-up, in lens position (centration)

Table 12-1 Definition for the Primary Effectiveness Endpoints

<i>i</i>	Lens Fit Assessment	Graded as
1	Lens movement (overall fit) at primary gaze	Acceptably tight Optimal fit Acceptably loose
2	Lens movement (overall fit) at peripheral gazes	Acceptably tight Optimal fit Acceptably loose
3	Lens position (centration)	Optimal lens centration Acceptable decentration

12.4.1.1 Statistical Hypotheses

At each visit, proportion of lenses graded as indicated in [Table 12-1](#) for each of the lens fit assessments (*i*) will be tested with the null and alternative hypotheses formulated in terms of the predefined margin of 0.05 for noninferiority.

$$H_0: P_i(T) - P_i(C) \leq -0.05$$

$$H_a: P_i(T) - P_i(C) > -0.05$$

where $i = 1, 2, 3$, and $P_i(T)$ and $P_i(C)$ denote the proportion of lenses defined for LID023681 and LID006961, respectively.

12.4.1.2 Analysis Methods

For each eye, a binary variable will be defined to indicate “success” if overall lens fit is graded as -1 (Acceptably Tight), 0 (Optimal), or 1 (Acceptably Loose), and ‘failure’ if graded as -2 (Unacceptably Tight) or 2 (Unacceptably Loose). Proportions of success will be analyzed using a generalized linear model with a logit link function, with terms for lens, period, sequence, visit, [REDACTED]

[REDACTED]

At each visit (Dispense, 6 Hour), a one-sided 95% lower confidence limit (LCL) will be calculated for the difference in proportions between the lenses (LID023681 minus LID006961). The null hypothesis will be rejected if the $LCL > -0.05$.

[REDACTED]

Crosstabulation summarizing overall lens fit of paired data will be displayed for LID023681 vs LID006961 at each visit, [REDACTED].

A similar statistical model and analysis method will be employed for lens movement at peripheral gazes and lens position.

[REDACTED]



12.5 Handling of Missing Data

All data obtained in evaluable subjects/eyes will be included in the analysis. No imputation for missing values will be carried out for the effectiveness analyses.

12.6 Safety Analysis

The safety endpoints are:

- Adverse events
- Biomicroscopy findings
- Device deficiencies

There are no safety hypotheses planned in this study. The focus of the safety analysis will be a comprehensive descriptive assessment of occurrence of adverse events as well as the other listed parameters.

All AEs occurring from the time a subject signs informed consent to study exit will be accounted for in the reporting. Safety analyses will be conducted using the safety analysis set on a treatment-emergent basis. Descriptive summaries (frequencies and percentages) for ocular and nonocular AEs will be presented by Medical Dictionary for Regulatory Activities Preferred Terms. AEs leading to study discontinuation, significant nonserious AEs, and SAEs will be identified. Individual subject listings will be provided, as necessary.

Individual subject listings will be provided for AEs that occur after signing informed consent but prior to exposure to study treatment, and for between-treatment AEs.

Each biomicroscopy parameter will be tabulated by its grade. For each biomicroscopy parameter, counts and percentages of eyes that experience an increase of ≥ 2 grades from baseline (last assessment prior to study product exposure for each period) to any subsequent visit within the same period will be presented. A supportive listing will be generated which will include all biomicroscopy data from all visits within the same period for those eyes experiencing the increase.

Two listings for device deficiencies, prior to exposure of study product and treatment emergent, will be provided. Additionally, each device deficiency category will be tabulated.

No inferential testing will be done for safety analysis.

12.7 Interim Analyses and Reporting

There are no plans to conduct an interim analysis and no criteria by which the study would be terminated early based upon statistical determination.

12.8 Sample Size Justification

Sample size calculation is based on several base curve optimization studies with Alcon lens materials.

Primary Effectiveness Endpoints

With an assumed difference of 0 in the proportion of optimal or acceptable fits/decentration and 0.051 for proportion of discordant pairs, 90% power can be attained with a sample size of 175 in rejecting the null hypothesis of inferiority (margin = 0.05; one-sided $\alpha=0.05$). Power increases to 93% and 96% with an increase in sample size of 200 and 250, respectively.



13 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS

13.1 Subject Confidentiality

The investigator must ensure that the subject's identity is kept confidential throughout the course of the study. In particular, the investigator must keep an enrollment log with confidential identifying information that corresponds to the subject numbers and initials of

each study participant. The study sponsor may collect a copy of the enrollment log ***without any directly identifying subject information.***

The study sponsor may share subject-level data collected in this trial with qualified researchers to help facilitate product development or enhancements in research that is not directly related to the study objectives. The informed consent explains this to the study subject.

13.2 Completion of Source Documents and Case Report Forms

The nature and location of all source documents will be identified to ensure that original data required to complete the case report forms (CRFs) exist and are accessible for verification by the site monitor, and all discrepancies shall be appropriately documented via the query resolution process. Site monitors are appointed by the study sponsor and are independent of study site staff.

If electronic records are maintained, the method of verification must be determined in advance of starting the study.

At a minimum, source documents include the following information for each subject:

- Subject identification (name, sex, race/ethnicity)
- Documentation of subject eligibility
- Date of informed consent
- Dates of visits
- Documentation that protocol specific procedures were performed
- Results of study parameters, as required by the protocol
- IP accountability records
- Documentation of AEs and other safety parameters (if applicable)
- Records regarding medical histories and the use of concomitant therapies prior to and during the study
- Date of study completion and reason for early discontinuation, if applicable

It is required that the author of an entry in the source documents be identifiable. Direct access to source documentation (medical records) must be allowed for the purpose of verifying that the data recorded on the CRF are consistent with the original source data.

Only designated individuals at the site will complete the CRFs. The CRFs must be completed at regular intervals following the clinical study visit schedule. It is expected that all data reported have corresponding entries in the source documents. The principal investigator is responsible for reviewing and certifying that the CRFs are accurate and complete. The only subject identifiers recorded on the CRFs will be subject number, and subject demographic information.

13.3 Data Review and Clarifications

A review of CRF data to the subject's source data will be completed by the site monitor to ensure completeness and accuracy. After the CRFs have been completed, additional data clarifications and/or additions may be needed as a result of the data cleaning process. Data clarifications are documented and are part of each subject's CRF.

13.4 Sponsor and Monitoring Responsibilities

The study sponsor will select principal investigators who are qualified by education, training, and experience to assume responsibility for the proper conduct of this clinical trial. For this study, the principal investigator and sub investigators must be health care professionals appropriately trained//certified to dispense contact lenses.

The study sponsor is financially funding this clinical trial and will compensate the investigator and/or the institution(s) at which the study is conducted in accordance with a signed clinical trial agreement.

The study sponsor will designate a monitor to conduct the appropriate site visits at the appropriate intervals according to the study monitoring plan. The clinical investigation will be monitored to ensure that the rights and well-being of the subjects are protected, the reported data are accurate, complete, and verifiable from the source documents, and the study is conducted in compliance with the current approved protocol (and amendments[s], if applicable), with current GCP, and with applicable regulatory requirements.

The site may not screen subjects or perform the informed consent process on any subject until it receives a notification from an appropriate study sponsor representative that the site may commence conducting study activities. Monitoring will be conducted periodically while the clinical study is ongoing. Monitoring methods may include site visits, telephone, written, and fax correspondence. Close-out visits will take place after the last visit of the last subject at the site, and after the database has locked.

A coordinating investigator may be identified by the study sponsor to review and endorse the final study report. In cases where a coordinating investigator is engaged, the study sponsor will select the coordinating investigator based upon their experience, qualifications, active study participation, and their willingness and availability to take on this role.

13.5 Regulatory Documentation and Records Retention

The investigator is required to maintain up-to-date, complete regulatory documentation as indicated by the study sponsor and the investigator's files will be reviewed as part of the ongoing study monitoring. Financial information is to be kept separately.

Additionally, the investigator must keep study records and source documents consistent with the terms of the clinical study agreement with the study sponsor. If the investigator retires, relocates, or for any other reason withdraws from responsibility of keeping the study records, then the study sponsor must be notified, and suitable arrangements made for retention of study records and source documents needed to comply with national and international regulations.

13.6 Quality Assurance and Quality Control

The study sponsor will secure agreement from all involved parties to ensure direct access to all study related sites, source data and documents, and reports for the purpose of monitoring and auditing by the study sponsor, and inspection by domestic and foreign regulatory authorities. Quality control will be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly. Agreements made by the study sponsor with the investigator/institution and any other parties involved in the clinical study will be provided in writing as part of the protocol or as a separate agreement.

14 ETHICS

Investigations are conducted in compliance with Good Clinical Practices (GCP); international and national regulations, laws and guidelines; ISO 14155; the conditions of approval imposed by reviewing IRBs/IECs or regulatory authorities; and in accordance with the ethical medical research principles outlined in the Declaration of Helsinki.

- The SOPs of the study sponsor and contract research organizations participating in the conduct of the clinical study and all other applicable regulations shall apply.
- Notifications and timelines for reporting protocol deviations should be based upon applicable Ethics Committee requirements.

The investigator must ensure that all personnel involved in the conduct of the study are qualified to perform their assigned responsibilities through relevant education, training, and experience. The investigator and all clinical study staff must conduct the clinical study in compliance with the protocol. The investigator is not allowed to deviate from the protocol except to protect the rights, safety, and well-being of human subjects under emergency circumstances. Emergency deviations may proceed without prior approval of the sponsor and the IRB/IEC, but shall be documented and reported to the sponsor and the IRB/IEC as soon as possible. Deviations from this protocol, regulatory requirements, and/or GCP must be recorded and reported to the sponsor prior to database lock. If needed, corrective and preventive action should be identified, implemented, and documented within the study records. Failure to implement identified corrective and preventative actions may result in site closure by the sponsor. Use of waivers to deviate from the clinical protocol is prohibited.

Before clinical study initiation, this protocol, the informed consent form, any other written information given to subjects, and any advertisements planned for subject recruitment must be approved by an IRB/IEC. The investigator must provide documentation of the IRB/IEC approval to the study sponsor. The approval must be dated and must identify the applicable protocol, amendments (if any), informed consent form, assent form (if any), all applicable recruiting materials, written information for subject, and subject compensation programs. The IRB/IEC must be provided with a copy of the package insert, any periodic safety updates, and all other information as required by local regulation and/or the IRB/IEC. Any additional requirements imposed by the IEC or regulatory authority shall be followed. At the end of the study, the investigator must notify the IRB/IEC about the study's completion. The IRB/IEC also must be notified if the study is terminated prematurely. Finally, the investigator must report to the IRB/IEC on the progress of the study at intervals stipulated by the IRB/IEC.

Voluntary informed consent must be obtained in writing from every subject. The obtaining of consent shall be documented before any procedure specific to the clinical investigation is performed on the subject.

The investigator must have a defined process for obtaining the required consent. Specifically, the investigator, or their delegate, must explain the clinical study to each potential subject and the subject must indicate voluntary consent by signing and dating the approved informed consent form. The subject must be provided an opportunity to ask questions of the investigator, and if required by local regulation, other qualified personnel. The investigator must provide the subject with a copy of the consent form written in a language the subject understands. The consent document must meet all applicable local laws and provide subjects with information regarding the purpose, procedures, requirements, and restrictions of the

study, along with any known risks and potential benefits associated with the IP and the study, the available compensation, and the established provisions for maintaining confidentiality of personal, protected health information. Subjects will be told about the voluntary nature of participation in the study and must be provided with contact information for the appropriate individuals should questions or concerns arise during the study. The subject also must be told that their records may be accessed by appropriate authorities and sponsor-designated personnel. The investigator must keep the original, signed copy of the consent (file in subject's medical records) and must provide a duplicate copy to each subject according to local regulations.

The investigator must have a defined process in case a subject would like to withdraw their consent(s). The investigator is the designated contact point for any such withdrawals.

The investigator must have a defined process in case a subject would like to exercise any of their rights under applicable Data Protection laws. The investigator is the designated contact point for any such requests.

The study sponsor assures that the key designs of this protocol will be registered on public databases where required by current regulations, and, as applicable, results will be posted.

15 REFERENCES

15.1 Regulations and Standards

The following references may be applicable in whole or in part for this clinical trial.

- ISO 11980 Ophthalmic optics - Contact lenses and contact lens care products - Guidance for clinical investigations
- EN ISO 14155 - Clinical Investigation of Medical Devices for Human Subjects - Good Clinical Practice
- 21 CFR Part 11 - Electronic Records; Electronic Signatures
- 21 CFR Part 50 - Protection of Human Subjects
- 21 CFR Part 56 - Institutional Review Boards
- 21 CFR Part 812 - Investigational Device Exemptions
- 21 CFR Part 54 - Financial Disclosure by Clinical Investigators
- The California Bill of Rights, if applicable

15.2 Scientific and Other References

Truong TN, Graham AD, Lin MC. Factors in Contact Lens Symptoms. *Optom Vis Sci.* 2014;91(2):133-141. doi: 10.1097/OPX.0000000000000138

